Evidence brief
Teduglutide
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein.
An established medicine that can reduce support given through a vein in short bowel syndrome. It needs intensive product-specific monitoring.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Gattex · ALX-0600 · GLP-2 analogue
Part of Gut peptide medicines
Words used here
- analog
- a changed version made to act like another substance
- outcome
- what the study measured
- randomized
- assigned to study groups by chance
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- peptide
- a short chain of amino acids
- indication
- the approved or studied use and patient group
- amino acid
- a small building block that makes peptides and proteins
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Randomized trials support reduction in parenteral-support requirements for short bowel syndrome.
Intestinal absorption, exposure, and product effects are characterized in the label and trials.
The label addresses neoplastic growth, obstruction, biliary and pancreatic disease, and fluid imbalance.
High for authentic Gattex used within its monitoring program.
02 · Identity
What it is
Teduglutide is a changed version of GLP-2, a body signal that affects intestinal absorption. Gattex is approved for people with short bowel syndrome who depend on parenteral support, such as fluids or nutrition given through a vein.
Scientific group: Glucagon-like peptide-2 analogue. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Gattex
2025 label- Formulation
- Powder and diluent for injection
- Route
- Subcutaneous
- Indication scope
- Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.
- Gattex
- Short bowel syndrome with dependence on parenteral support in labeled adults and children
04 · Research results
What the research shows
Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.
The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.
Exact product
Gattex evidence applies to a specific monitored prescription product. Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”
Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Teduglutide is a general gut-healing peptide.”
The approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The current Gattex indication. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Because teduglutide promotes intestinal growth, it is low risk.”
The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Approved Gattex use with required screening and monitoring. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Teduglutide
Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein. Approved products identified: Gattex.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.
The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.
07 · Safety
Safety limits for this record
This monitored prescription therapy has serious risks, including possible acceleration of neoplastic growth. No dosing, reconstitution, or self-treatment guidance is provided.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief based on the 2025 Gattex label, randomized trial, and orphan-drug record.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.